Latest1 information on COVID-19

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Trial ID: NCT04809584


The purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI scan.

Official Title

18F-DCFPyL PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-risk Prostate Cancer

Stanford Investigator(s)

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)


Inclusion Criteria:

   1. Patient is older than 18-year-old

   2. Biopsy proven prostate adenocarcinoma

   3. Planned prostatectomy with lymph node dissection

   4. Intermediate to high-risk disease (as determined by elevated Prostate-specific antigen
   (PSA) [PSA>10], T-stage [T2b or greater], Gleason score [Gleason score > 6] or other
   risk factors)

   5. Able to provide written consent

   6. Karnofsky performance status of ³50 (or Eastern Cooperative Oncology Group (ECOG)
   /World Health Organization (WHO) equivalent)

Exclusion Criteria:

   1. Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy including focal
   ablation techniques (HiFu)

   2. Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging

   3. Metallic implants (contraindicated for MRI)


drug: F18-DCFPyL

drug: Gadolinium

procedure: Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pranav Hedge